These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 16985240

  • 1. Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
    Longo DL.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1263-5. PubMed ID: 16985240
    [No Abstract] [Full Text] [Related]

  • 2. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma.
    Inogès S, Rodrìguez-Calvillo M, Zabalegui N, Lòpez-Dìaz de Cerio A, Villanueva H, Soria E, Suárez L, Rodríguez-Caballero A, Pastor F, García-Muñóz R, Panizo C, Pèrez-Calvo J, Melero I, Rocha E, Orfao A, Bendandi M, Grupo Español de Linfomas/Trasplante Autologo de Medula Oseo study group, Programa para el Estudio y Tratamiento de Hemopatias Malignas study group.
    J Natl Cancer Inst; 2006 Sep 20; 98(18):1292-301. PubMed ID: 16985248
    [Abstract] [Full Text] [Related]

  • 3. Anti-idiotypic Immunotherapy in follicular lymphoma patients: results of a long follow-up study.
    Yáñez R, Barrios Y, Ruiz E, Cabrera R, Díaz-Espada F.
    J Immunother; 2008 Apr 20; 31(3):310-2. PubMed ID: 18317357
    [Abstract] [Full Text] [Related]

  • 4. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I, Qin H, Kwak LW.
    Best Pract Res Clin Haematol; 2011 Jun 20; 24(2):295-304. PubMed ID: 21658625
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS, Lee ST, Qin H, Cha SC, Woo AF, Kwak LW.
    Expert Rev Vaccines; 2006 Jun 20; 5(3):381-94. PubMed ID: 16827622
    [Abstract] [Full Text] [Related]

  • 6. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma.
    Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES, Creekmore SP, Longo DL, Kwak LW.
    Nat Med; 1999 Oct 20; 5(10):1171-7. PubMed ID: 10502821
    [Abstract] [Full Text] [Related]

  • 7. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan 20; 1(1):67. PubMed ID: 16227966
    [No Abstract] [Full Text] [Related]

  • 8. Vaccination strategies in follicular lymphoma.
    Kannan S, Neelapu SS.
    Curr Hematol Malig Rep; 2009 Oct 20; 4(4):189-95. PubMed ID: 20425407
    [Abstract] [Full Text] [Related]

  • 9. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C, Simon F, Zirlik K, Heining-Mikesch K, Pfeifer D, Osterroth F, Rosenthal FM, Veelken H.
    Eur J Haematol; 2006 Nov 20; 77(5):395-402. PubMed ID: 16879605
    [Abstract] [Full Text] [Related]

  • 10. Idiotype vaccine strategies for treatment of follicular lymphoma.
    Mahaseth H, Brody JD, Sinha R, Shenoy PJ, Flowers CR.
    Future Oncol; 2011 Jan 20; 7(1):111-22. PubMed ID: 21174542
    [Abstract] [Full Text] [Related]

  • 11. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR.
    Expert Rev Vaccines; 2007 Jun 20; 6(3):307-17. PubMed ID: 17542746
    [Abstract] [Full Text] [Related]

  • 12. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M.
    Expert Rev Vaccines; 2004 Apr 20; 3(2):163-70. PubMed ID: 15056042
    [Abstract] [Full Text] [Related]

  • 13. Identifying patients with follicular lymphoma who are likely to benefit from an idiotype vaccine.
    Ansell SM, Suman VJ.
    J Clin Oncol; 2011 Jul 10; 29(20):2748-9. PubMed ID: 21632499
    [No Abstract] [Full Text] [Related]

  • 14. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype.
    Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R.
    J Clin Oncol; 2004 Dec 01; 22(23):4717-24. PubMed ID: 15483014
    [Abstract] [Full Text] [Related]

  • 15. Therapeutic idiotype vaccines for non-Hodgkin's lymphoma.
    Timmerman JM.
    Adv Pharmacol; 2004 Dec 01; 51():271-93. PubMed ID: 15464914
    [No Abstract] [Full Text] [Related]

  • 16. [Idiotype vaccines in the treatment of follicular lymphoma: current status and future perspectives].
    Zabalegui N, López Díaz de Cerio A, Inogés S, Soria E, Villanueva H, Rivero P.
    An Sist Sanit Navar; 2009 Dec 01; 32(1):61-73. PubMed ID: 19430512
    [Abstract] [Full Text] [Related]

  • 17. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma.
    Schuster SJ, Neelapu SS, Gause BL, Janik JE, Muggia FM, Gockerman JP, Winter JN, Flowers CR, Nikcevich DA, Sotomayor EM, McGaughey DS, Jaffe ES, Chong EA, Reynolds CW, Berry DA, Santos CF, Popa MA, McCord AM, Kwak LW.
    J Clin Oncol; 2011 Jul 10; 29(20):2787-94. PubMed ID: 21632504
    [Abstract] [Full Text] [Related]

  • 18. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
    Villanueva H, de Cerio AL, Inoges S, Pastor F, Soldevilla MM, Bendandi M.
    Expert Rev Vaccines; 2011 Dec 10; 10(12):1661-9. PubMed ID: 22085168
    [Abstract] [Full Text] [Related]

  • 19. Cancer vaccine strategies get bigger and better.
    de Gruijl TD, Curiel DT.
    Nat Med; 1999 Oct 10; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract] [Full Text] [Related]

  • 20. Feasibility of idiotype vaccination in relapsed B-cell malignancies.
    Inogés S, Rodríguez-Calvillo M, López-Díaz de Cerio A, Zabalegui N, Pérez-Calvo J, Panizo C, Hernandez M, Cuesta B, Rocha E, Bendandi M.
    Haematologica; 2003 Dec 10; 88(12):1438-40. PubMed ID: 14688006
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.